Article By:
ChinaBio® Today
Saturday, November 27, 2021 2:30 PM EDT
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to acquire Zenas shares up to 15% of Zenas’ equity.